Studio clinico NCT06810544 · Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma

Studio clinico NCT06810544 (fase I/II) risulta «in reclutamento» su ClinicalTrials.gov.

Patologia: Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma · Interventi registrati: TNG456, abemaciclib · Date registrate (fonte): 2025-03-24, 2027-03-31, 2025-02-05, 2026-10-16.

Sintesi dello studio (fonte: ClinicalTrials.gov, testo originale in inglese):

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.

Fonte: https://clinicaltrials.gov/study/NCT06810544